1
|
Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, Mishani E, Even-Sapir E. Head-to-head comparison of [ 68Ga]Ga-FAPI-04 and [ 18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging 2021; 49:743-750. [PMID: 34302504 PMCID: PMC8803763 DOI: 10.1007/s00259-021-05494-x] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2021] [Accepted: 07/08/2021] [Indexed: 12/31/2022]
Abstract
BACKGROUND [18F]-Fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) may sometimes be suboptimal for imaging gastric adenocarcinoma. The recently introduced [68Ga]Ga-FAPI-04 (FAPI) PET/CT targets tumor stroma and has shown considerable potential in evaluating the extent of disease in a variety of tumors. METHODS We performed a head-to-head prospective comparison of FAPI and FDG PET/CT in the same group of 13 patients with gastric adenocarcinoma who presented for either initial staging (n = 10) or restaging (n = 3) of disease. Lesion detection and maximum standardized uptake value (SUVmax) were compared between the two types of radiotracers. RESULTS All ten primary gastric tumors were FAPI-positive (100% detection rate), whereas only five were also FDG-positive (50%). SUVmax was not significantly different, but the tumor-to-background ratio was higher for FAPI (mean, median, and range of 4.5, 3.2, and 0.8-9.7 for FDG and 12.9, 11.9, and 2.2-23.9 for FAPI, P = 0.007). The level of detection of regional lymph node involvement was comparable. FAPI showed a superior detection rate for peritoneal carcinomatosis (100% vs. none). Two patients with widespread peritoneal carcinomatosis underwent a follow-up FAPI scan after chemotherapy: one showed partial remission and the other showed progressive disease. CONCLUSIONS The findings of this pilot study suggest that FAPI PET/CT outperforms FDG PET/CT in detecting both primary gastric adenocarcinoma and peritoneal carcinomatosis from gastric cancer. FAPI PET/CT also shows promise for monitoring response to treatment in patients with peritoneal carcinomatosis from gastric cancer; however, larger trials are needed to validate these preliminary findings.
Collapse
Affiliation(s)
- Jonathan Kuten
- Department of Nuclear Medicine, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, 6 Weizmann St, 6423906 Tel Aviv, Israel
| | - Charles Levine
- Department of Nuclear Medicine, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, 6 Weizmann St, 6423906 Tel Aviv, Israel
| | - Ofer Shamni
- Cyclotron Radiochemistry Unit, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Sharon Pelles
- Division of Oncology, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ido Wolf
- Division of Oncology, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Guy Lahat
- Department of Surgery, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eyal Mishani
- Cyclotron Radiochemistry Unit, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Einat Even-Sapir
- Department of Nuclear Medicine, Tel Aviv Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, 6 Weizmann St, 6423906 Tel Aviv, Israel
| |
Collapse
|
2
|
Orevi M, Shamni O, Zalcman N, Chicheportiche A, Mordechai A, Moscovici S, Shoshan Y, Shahar T, Charbit H, Gutreiman M, Paldor I, Mishani E, Lossos A, Lavon I. [ 18F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma. Neurooncol Adv 2021; 3:vdab019. [PMID: 33738450 PMCID: PMC7954111 DOI: 10.1093/noajnl/vdab019] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background G lioblastoma (GBM) is associated with poor overall survival. Recently, we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and AR antagonists induced dose-dependent death in several GBM cell lines and significantly reduced tumor growth and prolonged the lifespan of mice implanted with human GBM. 16β-18F-fluoro-5α-dihydrotestosterone ([18F]-FDHT) is a positron emission tomography (PET) tracer used to detect AR expression in prostate and breast cancers. This study was aimed at exploring the ability of [18F]-FDHT-PET to detect AR expression in high-grade gliomas. Methods Twelve patients with suspected high-grade glioma underwent a regular workup and additional dynamic and static [18F]-FDHT-PET/CT. Visual and quantitative analyses of [18 F]-FDHT kinetics in the tumor and normal brain were performed. Mean and maximum (max) standardized uptake values (SUVs) were determined in selected volumes of interest. The patients had surgery or biopsy after PET/CT. AR protein was analyzed in the tumor samples by western blot. Fold change in AR expression was calculated by densitometry analysis. Correlation between imaging and AR protein samples was determined. Results In six of the 12 patients, [18 F]-FDHT uptake was significantly higher in the tumor than in the normal brain. These patients also had increased AR protein expression within the tumor. Pearson correlation coefficient analysis for the tumor-to-control normal brain uptake ratio in terms of SUVmean versus AR protein expression was positive and significant (R = 0.84; P = .002). Conclusion [18 F]-FDHT-PET/CT could identify increased AR expression in high-grade glioma.
Collapse
Affiliation(s)
- Marina Orevi
- Department of Nuclear Medicine and Biophysics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Ofer Shamni
- Cyclotron/Radiochemistry Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Nomi Zalcman
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Alexandre Chicheportiche
- Department of Nuclear Medicine and Biophysics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Anat Mordechai
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Samuel Moscovici
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Yigal Shoshan
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Tal Shahar
- The Laboratory for Molecular Neuro-Oncology, Department of Neurosurgery, Shaare Zedek-Hebrew University Medical Center, Jerusalem, Israel
| | - Hanna Charbit
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Mijal Gutreiman
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Iddo Paldor
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Eyal Mishani
- Cyclotron/Radiochemistry Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Alexander Lossos
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Iris Lavon
- Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.,Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| |
Collapse
|
3
|
Mordechai A, Shamni O, Zalcman N, Moscovici S, Chicheportiche A, Shoshan Y, Shahar T, Charbit H, Guterman M, Paldor I, Mishani E, Lossos A, Orevi M, Lavon I. NIMG-30. PET IMAGING OF ANDROGEN RECEPTOR EXPRESSION IN PATIENTS WITH GBM USING [18F]-FDHT. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
GBM is associated with poor overall survival partly due to lack of effective treatment. Recently we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and that AR antagonists induced dose-dependent death in several glioblastoma cell lines. Treatment of mice implanted with human GBM with AR antagonists significantly reduced the growth of the tumor and prolonged the lifespan of the mice. 18f-fluorine-radiolabeled Dihidrotestosteron (DHT), a natural ligand of AR, [16β-18F-fluoro-5α-dihydrotestosterone ([18F]-FDHT)] is one of the PET tracers used to detect AR expression in metastatic prostate cancer. The aim of this study was to identify AR-expressing GBM tumors in real time using PET-CT scan with [18F]-FDHT.
MATERIALS AND METHODS
Twelve patients with GBM underwent a dynamic (first 30 min) and whole body static (later 60-80 min) [18F]-FDHT PET/CT (296-370 MBq) scans 2-4 days prior to the surgery or biopsy. Protein was extracted from the tumor and subjected to western blot analysis. AR Protein fold change of each tumor sample was calculated by densitometry analysis compared with that of normal brain, following normalization to GAPDH.
RESULTS
At ~60 min after injection, 6 of the 12 patients showed significantly higher tumor accumulation of [18F]-FDHT, compared to reference tissue (SUV/Control)mean: 1.33-2.63 fold, (SUV/control)max: 1.4-3.43 fold. The patient who had higher tumor accumulation of [18F]-FDHT, demonstrated also high (1.6-2.27 fold/normal brain) AR protein expression within the tumor. Pearson-correlation-coefficient analysis for the (SUV/Control)mean at ~60 min after the injection versus AR protein expression, was positive and significant (R=0.841;p=0.0024).
CONCLUSION
This study demonstrated for the first time that [18F]-FDHT PET can identify AR-positive-GBM-tumors (with sensitivity and specificity at 100%) and may therefore be a powerful tool to select patients eligible for treatment with AR antagonists. It could possibly be employed also to monitor treatment response and/or progression during the course of therapy.
Collapse
Affiliation(s)
- Anat Mordechai
- Leslie and Michael Gaffin Center for Neuro-Oncology and Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Ofer Shamni
- Cyclotron/Radiochemistry/ MicroPET Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Nomi Zalcman
- Leslie and Michael Gaffin Center for Neuro-Oncology and Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Samuel Moscovici
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Alexandre Chicheportiche
- Department of Nuclear Medicine and Biophysics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Yigal Shoshan
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Tal Shahar
- The Laboratory for Molecular Neuro-Oncology, Department of Neurosurgery, Shaare-Zedek medical center, Jerusalem, Israel
| | - Hanna Charbit
- Leslie and Michael Gaffin Center for Neuro-Oncology and Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Mijal Guterman
- Leslie and Michael Gaffin Center for Neuro-Oncology and Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Iddo Paldor
- Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Eyal Mishani
- Cyclotron/Radiochemistry/ MicroPET Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Alexander Lossos
- Leslie and Michael Gaffin Center for Neuro-Oncology and Department of Neurology, Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Marina Orevi
- Department of Nuclear Medicine and Biophysics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Iris Lavon
- Leslie and Michael Gaffin Center for Neuro-Oncology and Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| |
Collapse
|
4
|
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med 2019; 61:527-532. [DOI: 10.2967/jnumed.119.234187] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 08/26/2019] [Indexed: 11/16/2022] Open
|
5
|
Shamni O, Nebeling B, Grievink H, Mishani E. Fine-tuning of the automated [18
F]PSMA-1007 radiosynthesis. J Labelled Comp Radiopharm 2019; 62:252-258. [DOI: 10.1002/jlcr.3732] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 03/25/2019] [Accepted: 03/27/2019] [Indexed: 01/25/2023]
Affiliation(s)
- Ofer Shamni
- Cyclotron/Radiochemistry/MicroPET Unit; Hadassah Hebrew University Hospital, Hadassah Medical Organization; Jerusalem Israel
| | | | - Hilbert Grievink
- Cyclotron/Radiochemistry/MicroPET Unit; Hadassah Hebrew University Hospital, Hadassah Medical Organization; Jerusalem Israel
| | - Eyal Mishani
- Cyclotron/Radiochemistry/MicroPET Unit; Hadassah Hebrew University Hospital, Hadassah Medical Organization; Jerusalem Israel
| |
Collapse
|
6
|
Shamni O, Cohen G, Gruzman A, Zaid H, Klip A, Cerasi E, Sasson S. Supportive data on the regulation of GLUT4 activity by 3-O-methyl-D-glucose. Data Brief 2017; 14:329-336. [PMID: 28795110 PMCID: PMC5547241 DOI: 10.1016/j.dib.2017.07.069] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 07/12/2017] [Accepted: 07/25/2017] [Indexed: 11/29/2022] Open
Abstract
The data presented in this article are related to the research article entitled “Regulation of GLUT4 activity in myotubes by 3-O-methyl-D-glucose” (Shamni et al., 2017) [1]. These data show that the experimental procedures used to analyze the effects of 3-O-methyl-D-glucose (MeGlc) on the rate of hexose transport into myotubes were valid and controlled. The stimulatory effect of MeGlc was limited to glucose transporter 4 (GLUT4) and was independent of ambient glucose and protein synthesis. Cornish-Bowden kinetic analysis of uptake data revealed that MeGlc attenuated indinavir-induced inhibition of hexose transport in a competitive manner.
Collapse
Affiliation(s)
- Ofer Shamni
- The Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Guy Cohen
- The Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Arie Gruzman
- The Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Hilal Zaid
- Program in Cell Biology, Hospital for Sick Children, Toronto, OT, Canada M5G 1XB
| | - Amira Klip
- Program in Cell Biology, Hospital for Sick Children, Toronto, OT, Canada M5G 1XB
| | - Erol Cerasi
- Endocrinology and Metabolism Service, Department of Internal Medicine, The Hebrew University-Hadassah Medical Center, Jerusalem 9112001, Israel
| | - Shlomo Sasson
- The Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
- Corresponding author.
| |
Collapse
|
7
|
Shamni O, Cohen G, Gruzman A, Zaid H, Klip A, Cerasi E, Sasson S. Regulation of GLUT4 activity in myotubes by 3-O-methyl-d-glucose. Biochim Biophys Acta Biomembr 2017. [PMID: 28648676 DOI: 10.1016/j.bbamem.2017.06.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The rate of glucose influx to skeletal muscles is determined primarily by the number of functional units of glucose transporter-4 (GLUT4) in the myotube plasma membrane. The abundance of GLUT4 in the plasma membrane is tightly regulated by insulin or contractile activity, which employ distinct pathways to translocate GLUT4-rich vesicles from intracellular compartments. Various studies have indicated that GLUT4 intrinsic activity is also regulated by conformational changes and/or interactions with membrane components and intracellular proteins in the vicinity of the plasma membrane. Here we show that the non-metabolizable glucose analog 3-O-methyl-d-glucose (MeGlc) augmented the rate of hexose transport into myotubes by increasing GLUT4 intrinsic activity without altering the content of the transporter in the plasma membrane. This effect was not a consequence of ATP depletion or hyperosmolar stress and did not involve Akt/PKB or AMPK signal transduction pathways. MeGlc reduced the inhibitory potency (increased Ki) of indinavir, a selective inhibitor of GLUT4, in a dose-dependent manner. Kinetic analyses indicate that MeGlc induced changes in GLUT4 or GLUT4 complexes within the plasma membrane, which enhanced the hexose transport activity and reduced the potency of indinavir inhibition. Finally, we present a simple kinetic analysis for screening and discovering low molecular weight compounds that augment GLUT4 activity.
Collapse
Affiliation(s)
- Ofer Shamni
- Department of Nuclear Medicine, the Hebrew University-Hadassah Medical Center, Jerusalem 9112001, Israel; Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Guy Cohen
- The Skin Research Institute, The Dead-Sea & Arava Science Center, Israel; Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Arie Gruzman
- Division of Medicinal Chemistry, Dept. of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel
| | - Hilal Zaid
- Al-Qasemi Research Center, Al-Qasemi Academy, Baqa-El-Gharbia 3010000, Israel; Program in Cell Biology, Hospital for Sick Children, Toronto, OT M5G 1XB, Canada
| | - Amira Klip
- Program in Cell Biology, Hospital for Sick Children, Toronto, OT M5G 1XB, Canada
| | - Erol Cerasi
- Endocrinology and Metabolism Service, Department of Internal Medicine, The Hebrew University-Hadassah Medical Center, Jerusalem 9112001, Israel
| | - Shlomo Sasson
- Institute for Drug Research, Section of Pharmacology, Diabetes Research Unit, Faculty of Medicine, The Hebrew University, Jerusalem 9112102, Israel.
| |
Collapse
|
8
|
Cohen G, Shamni O, Avrahami Y, Cohen O, Broner EC, Filippov-Levy N, Chatgilialoglu C, Ferreri C, Kaiser N, Sasson S. Beta cell response to nutrient overload involves phospholipid remodelling and lipid peroxidation. Diabetologia 2015; 58:1333-43. [PMID: 25810039 DOI: 10.1007/s00125-015-3566-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Accepted: 03/11/2015] [Indexed: 12/13/2022]
Abstract
AIMS/HYPOTHESIS Membrane phospholipids are the major intracellular source for fatty acid-derived mediators, which regulate myriad cell functions. We showed previously that high glucose levels triggered the hydrolysis of polyunsaturated fatty acids from beta cell phospholipids. These fatty acids were subjected to free radical-catalysed peroxidation to generate the bioactive aldehyde 4-hydroxy-2E-nonenal (4-HNE). The latter activated the nuclear peroxisome proliferator-activated receptor-δ (PPARδ), which in turn augmented glucose-stimulated insulin secretion. The present study aimed at investigating the combined effects of glucose and fatty acid overload on phospholipid turnover and the subsequent generation of lipid mediators, which affect insulin secretion and beta cell viability. METHODS INS-1E cells were incubated with increasing glucose concentrations (5-25 mmol/l) without or with palmitic acid (PA; 50-500 μmol/l) and taken for fatty acid-based lipidomic analysis and functional assays. Rat isolated islets of Langerhans were used similarly. RESULTS PA was incorporated into membrane phospholipids in a concentration- and time-dependent manner; incorporation was highest at 25 mmol/l glucose. This was coupled to a rapid exchange with saturated, mono-unsaturated and polyunsaturated fatty acids. Importantly, released arachidonic acid and linoleic acid were subjected to peroxidation, resulting in the generation of 4-HNE, which further augmented insulin secretion by activating PPARδ in beta cells. However, this adaptive increase in insulin secretion was abolished at high glucose and PA levels, which induced endoplasmic reticulum stress, apoptosis and cell death. CONCLUSIONS/INTERPRETATION These findings highlight a key role for phospholipid remodelling and fatty acid peroxidation in mediating adaptive and cytotoxic interactions induced by nutrient overload in beta cells.
Collapse
Affiliation(s)
- Guy Cohen
- Department of Pharmacology, Institute for Drug Research, Faculty of Medicine, The Hebrew University, Jerusalem, 9112102, Israel
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Cohen G, Riahi Y, Shamni O, Guichardant M, Chatgilialoglu C, Ferreri C, Kaiser N, Sasson S. Role of lipid peroxidation and PPAR-δ in amplifying glucose-stimulated insulin secretion. Diabetes 2011; 60:2830-42. [PMID: 21896929 PMCID: PMC3198069 DOI: 10.2337/db11-0347] [Citation(s) in RCA: 270] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Previous studies show that polyunsaturated fatty acids (PUFAs) increase the insulin secretory capacity of pancreatic β-cells. We aimed at identifying PUFA-derived mediators and their cellular targets that are involved in the amplification of insulin release from β-cells preexposed to high glucose levels. RESEARCH DESIGN AND METHODS The content of fatty acids in phospholipids of INS-1E β-cells was determined by lipidomics analysis. High-performance liquid chromatography was used to identify peroxidation products in β-cell cultures. Static and dynamic glucose-stimulated insulin secretion (GSIS) assays were performed on isolated rat islets and/or INS-1E cells. The function of peroxisome proliferator-activated receptor-δ (PPAR-δ) in regulating insulin secretion was investigated using pharmacological agents and gene expression manipulations. RESULTS High glucose activated cPLA(2) and, subsequently, the hydrolysis of arachidonic and linoleic acid (AA and LA, respectively) from phospholipids in INS-1E cells. Glucose also increased the level of reactive oxygen species, which promoted the peroxidation of these PUFAs to generate 4-hydroxy-2E-nonenal (4-HNE). The latter mimicked the GSIS-amplifying effect of high glucose preexposure and of the PPAR-δ agonist GW501516 in INS-1E cells and isolated rat islets. These effects were blocked with GSK0660, a selective PPAR-δ antagonist, and the antioxidant N-acetylcysteine or by silencing PPAR-δ expression. High glucose, 4-HNE, and GW501516 also induced luciferase expression in a PPAR-δ-mediated transactivation assay. Cytotoxic effects of 4-HNE were observed only above the physiologically effective concentration range. CONCLUSIONS Elevated glucose levels augment the release of AA and LA from phospholipids and their peroxidation to 4-HNE in β-cells. This molecule is an endogenous ligand for PPAR-δ, which amplifies insulin secretion in β-cells.
Collapse
Affiliation(s)
- Guy Cohen
- Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, Hebrew University, Jerusalem, Israel
| | - Yael Riahi
- Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, Hebrew University, Jerusalem, Israel
| | - Ofer Shamni
- Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, Hebrew University, Jerusalem, Israel
| | - Michel Guichardant
- CarMeN Laboratory, Lyon University, INSA de Lyon, INSERM U1060, Université de Lyon-1, Villeurbanne, France
| | | | - Carla Ferreri
- ISOF-BioFreeRadicals, Consiglio Nazionale delle Ricerche, Bologna, Italy
| | - Nurit Kaiser
- Endocrinology and Metabolism Service, Department of Medicine, Hadassah–Hebrew University Medical Center, Jerusalem, Israel
| | - Shlomo Sasson
- Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, Hebrew University, Jerusalem, Israel
- Corresponding author: Shlomo Sasson,
| |
Collapse
|
10
|
Negre-Salvayre A, Auge N, Ayala V, Basaga H, Boada J, Brenke R, Chapple S, Cohen G, Feher J, Grune T, Lengyel G, Mann GE, Pamplona R, Poli G, Portero-Otin M, Riahi Y, Salvayre R, Sasson S, Serrano J, Shamni O, Siems W, Siow RCM, Wiswedel I, Zarkovic K, Zarkovic N. Pathological aspects of lipid peroxidation. Free Radic Res 2010; 44:1125-71. [PMID: 20836660 DOI: 10.3109/10715762.2010.498478] [Citation(s) in RCA: 474] [Impact Index Per Article: 33.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Lipid peroxidation (LPO) product accumulation in human tissues is a major cause of tissular and cellular dysfunction that plays a major role in ageing and most age-related and oxidative stress-related diseases. The current evidence for the implication of LPO in pathological processes is discussed in this review. New data and literature review are provided evaluating the role of LPO in the pathophysiology of ageing and classically oxidative stress-linked diseases, such as neurodegenerative diseases, diabetes and atherosclerosis (the main cause of cardiovascular complications). Striking evidences implicating LPO in foetal vascular dysfunction occurring in pre-eclampsia, in renal and liver diseases, as well as their role as cause and consequence to cancer development are addressed.
Collapse
|
11
|
Abstract
The peroxidation of n-3 and n-6 polyunsaturated fatty acids (PUFAs) and of their hydroperoxy metabolites is a complex process. It is initiated by free oxygen radical-induced abstraction of a hydrogen atom from the lipid molecule followed by a series of nonenzymatic reactions that ultimately generate the reactive aldehyde species 4-hydroxyalkenals. The molecule 4-hydroxy-2E-hexenal (4-HHE) is generated by peroxidation of n-3 PUFAs, such as linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid. The aldehyde product 4-hydroxy-2E-nonenal (4-HNE) is the peroxidation product of n-6 PUFAs, such as arachidonic and linoleic acids and their 15-lipoxygenase metabolites, namely 15-hydroperoxyeicosatetraenoic acid (15-HpETE) and 13-hydroperoxyoctadecadienoic acid (13-HpODE). Another reactive peroxidation product is 4-hydroxy-2E,6Z-dodecadienal (4-HDDE), which is derived from 12-hydroperoxyeicosatetraenoic acid (12-HpETE), the 12-lipoxygenase metabolite of arachidonic acid. Hydroxyalkenals, notably 4-HNE, have been implicated in various pathophysiological interactions due to their chemical reactivity and the formation of covalent adducts with macromolecules. The progressive accumulation of these adducts alters normal cell functions that can lead to cell death. The lipophilicity of these aldehydes positively correlates to their chemical reactivity. Nonetheless, at low and noncytotoxic concentrations, these molecules may function as signaling molecules in cells. This has been shown mostly for 4-HNE and to some extent for 4-HHE. The capacity of 4-HDDE to generate such "mixed signals" in cells has received less attention. This review addresses the origin and cellular functions of 4-hydroxyalkernals.
Collapse
Affiliation(s)
- Yael Riahi
- Dept. of Pharmacology, The Hebrew Univ. Jerusalem 91120, Israel
| | | | | | | |
Collapse
|
12
|
Gruzman A, Shamni O, Ben Yakir M, Sandovski D, Elgart A, Alpert E, Cohen G, Hoffman A, Katzhendler Y, Cerasi E, Sasson S. Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. J Med Chem 2009; 51:8096-108. [PMID: 19049348 DOI: 10.1021/jm8008713] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense. We have discovered that D-xylose increases the rate of glucose transport in a non-insulin-dependent manner in rat and human myotubes in vitro. Due to the unfavorable pharmacokinetic properties of D-xylose we aimed at synthesizing active derivatives with improved parameters. Quantitative structure-activity relationship analysis identified critical hydroxyl groups in D-xylose. These data were used to synthesize various hydrophobic derivatives of D-xylose of which compound 19 the was most potent compound in stimulating the rate of hexose transport by increasing the abundance of glucose transporter-4 in the plasma membrane of myotubes. This effect resulted from the activation of AMP-activated protein kinase without recruiting the insulin transduction mechanism. These results show that lipophilic D-xylose derivatives may serve as prototype molecules for the development of novel antihyperglycemic drugs for the treatment of diabetes.
Collapse
Affiliation(s)
- Arie Gruzman
- Department of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University, 91120 Jerusalem, Israel
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|